Li Ning, Zhang Jiahui, Meng Xiaojiao, Yao Wenliang
Department of Ultrasound Medicine, Zibo Central Hospital, 255022 Zibo, Shandong Province, China.
Department of Public Health, Zibo Central Hospital, 255022 Zibo, Shandong Province, China.
J Healthc Eng. 2022 Mar 29;2022:7851436. doi: 10.1155/2022/7851436. eCollection 2022.
The aim of this study is to explore the clinical application value of high-frequency ultrasound combined with detection of serum high mobility group box (HMGB-1), soluble IL-2 receptor (SIL-2R), and thyroglobulin antibody (TgAb) in diagnosing thyroid cancer.
By means of retrospective study, 50 thyroid cancer patients treated in our hospital from January 2019 to January 2021 were selected as the thyroid cancer group, 50 patients with benign thyroid lesions were included in the benign lesion group, and 50 healthy individuals examined in our hospital in the same period were included in the control group. All study objects received high-frequency ultrasound examination, and at the same time, their serum HMGB-1, SIL-2R, and TgAb levels were measured. After that, the results of high-frequency ultrasound examination were analyzed, the diagnostic efficacy of different diagnosis methods was explored, and receiver operating characteristic (ROC) curves were plotted.
According to the results of high-frequency ultrasound examination, there were significant differences in echogenicity surrounding and inside the lesion, calcification, blood flow distribution, and blood flow parameters between the thyroid cancer group and the benign lesion group ( < 0.001); the HMGB-1, SIL-2R, and TgAb levels were statistically different among the three groups ( < 0.001), and the level values of HMGB-1, SIL-2R, and TgAb of the thyroid cancer group were, respectively, (12.26 ± 1.32) ng/ml, (108.65 ± 9.75) pmol/L, and (690.65 ± 34.47) IU/mL; the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of high-frequency ultrasound combined with detection of serum HMGB-1, SIL-2R, and TgAb were, respectively, 98.0%, 95.0%, 90.7%, and 99.0%, and AUC (95%CI) = 0.965 (0.931-0.999).
High-frequency ultrasound combined with detection of serum HMGB-1, SIL-2R, and TgAb has a good value in diagnosing thyroid cancer, which should be promoted in practice.
本研究旨在探讨高频超声联合血清高迁移率族蛋白盒1（HMGB - 1）、可溶性白细胞介素 - 2受体（SIL - 2R）及甲状腺球蛋白抗体（TgAb）检测在甲状腺癌诊断中的临床应用价值。
采用回顾性研究方法，选取2019年1月至2021年1月在我院接受治疗的50例甲状腺癌患者作为甲状腺癌组，50例甲状腺良性病变患者作为良性病变组，同期在我院体检的50例健康个体作为对照组。所有研究对象均接受高频超声检查，同时检测其血清HMGB - 1、SIL - 2R及TgAb水平。之后，分析高频超声检查结果，探讨不同诊断方法的诊断效能，并绘制受试者工作特征（ROC）曲线。
根据高频超声检查结果，甲状腺癌组与良性病变组在病变周边及内部回声、钙化、血流分布及血流参数方面存在显著差异（<0.001）；三组间HMGB - 1、SIL - 2R及TgAb水平差异有统计学意义（<0.001），甲状腺癌组HMGB - 1、SIL - 2R及TgAb的水平值分别为（12.26±1.32）ng/ml、（108.65±9.75）pmol/L及（690.65±34.47）IU/mL；高频超声联合血清HMGB - 1、SIL - 2R及TgAb检测的灵敏度、特异度、阳性预测值（PPV）及阴性预测值（NPV）分别为98.0%、95.0%、90.7%及99.0%，曲线下面积（AUC，95%CI）=0.965（0.931 - 0.999）。
高频超声联合血清HMGB - 1、SIL - 2R及TgAb检测在甲状腺癌诊断中具有良好价值，应在实际中推广应用。
Zotero 插件